The nomogram incorporating EGFR mutation status which could facilitate the 3‐ and 5‐year overall survival prediction for individual stage III NSCLC patients treated with definitive chemoradiotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.